Mitsubishi Tanabe awarded $117m in Remicade supply settlement
This article was originally published in Scrip
Executive Summary
A decision by Mitsubishi Tanabe Pharma (MTP) to take a dispute with Janssen Biotech to the International Chamber of Commerce (ICC) has paid off for the Japanese firm, which has been awarded $117m in relation to the supply pricing of Remicade (infliximab) by its licensing partner.